Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Managing toxicities associated with CAR-T therapies

Michael Wang • 8 Jun 2021
EHA 2021
General Antibodies Cetuximab Rituximab Tocilizumab

Michael L. Wang, MD, MD Anderson Cancer Center, Houston, TX, discusses the management of toxicities associated with chimeric antigen receptor T-cell (CAR-T) therapies. Prof. Wang outlines four main categories of CAR-T associated toxicities: cytokine release syndrome (CRS), neurotoxicities, infection-related toxicities and other toxicities including hypertension, hypoxia and hypophosphatemia. For CRS, Prof. Wang highlights the use of steroids. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Michael Wang

3:37
SYMPATICO: ibrutinib combined with venetoclax in patients with R/R MCL
Michael Wang • 11 Dec 2023
1:57
Improvements and remaining challenges in treating R/R MCL after failure of BTK inhibitors
Michael Wang • 6 Sep 2023
1:18
BRUIN study cohort update: pirtobrutinib for patients with MCL
Michael Wang • 6 Sep 2023
2:27
Lisocabtagene maraleucel for R/R MCL: TRANSCEND-NHL-001 update
Michael Wang • 6 Sep 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals